Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

1362602

USP

Levonorgestrel

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

D(−)-Norgestrel, 13β-Ethyl-17α-ethinyl-17β-hydroxygon-4-en-3-on, 17α-Ethinyl-18-homo-19-nortestosteron, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-in-3-on, 18,19-Dinor-4-pregnen-20-in-3-on, Levonorgestrel

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C21H28O2
CAS-Nummer:
797-63-7
Molekulargewicht:
312.45
MDL-Nummer:
MFCD00199013
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329750050
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

levonorgestrel

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChIKey

WWYNJERNGUHSAO-XUDSTZEESA-N

Angaben zum Gen

human ... PGR(5241)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Levonorgestrel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Piktogramme

Health hazard
GHS08

Signalwort

Danger

Gefahreneinstufungen

Carc. 2 - Lact. - Repr. 1A

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 5

1 of 5

Ethinylestradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1480

Ethinylestradiol

Norethindron United States Pharmacopeia (USP) Reference Standard

USP

1469005

Norethindron

Ethinylestradiol European Pharmacopoeia (EP) Reference Standard

E1900000

Ethinylestradiol

Sigma-Aldrich

Sigma-Aldrich

89904

Mikropartikel auf Polystyrolbasis

17α-Ethinylestradiol ≥98%

Sigma-Aldrich

E4876

17α-Ethinylestradiol

Ian S Fraser
Contraception, 87(3), 273-279 (2012-10-09)
It has been recognized for well over half a century that hormonal preparations designed as contraceptives are also capable of offering health benefits through the treatment and prevention of benign gynecological disease and even some systemic conditions. Increasing attention is
Ahmed M Abou-Setta et al.
The Cochrane database of systematic reviews, 1(1), CD005072-CD005072 (2013-02-27)
Various options exist for treating endometriosis, including surgical, medical, such as ovarian suppression, or a combination of these strategies. Surgical treatment of endometriosis aims to remove visible areas of endometriosis. The aim of medical therapy is to inhibit growth of
T E Roberts et al.
BMJ (Clinical research ed.), 342, d2202-d2202 (2011-04-28)
To undertake a cost effectiveness analysis comparing first and second generation endometrial ablative techniques, hysterectomy, and the levonorgestrel releasing intrauterine system (Mirena) for treating heavy menstrual bleeding. Model based economic evaluation with data from an individual patient data meta-analysis supplemented
H K Kroupova et al.
Aquatic toxicology (Amsterdam, Netherlands), 154, 154-162 (2014-06-04)
The aim of the present study was to investigate the effects of the synthetic progestin levonorgestrel (LNG) on the reproductive endocrine system of a teleost fish, the roach (Rutilus rutilus). Pubertal roach were exposed for 28 days in a flow-through
Diana Mansour
Contraception, 85(3), 224-234 (2011-11-10)
The contraceptive profile of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena®) is well established, with efficacy similar to that achieved with sterilization and rapid return to fertility after discontinuation of use. The LNG-IUS is typically associated with transient menstrual disturbance during
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.